ArticleMolecules (Basel, Switzerland)2022
Whole-Genome Analysis of
Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 6 citations in OpenAlex.
- A novel Acinetobacter phage reveals altered virulence traits in phage-resistant strains.Virulence · 2026Article
- Decoding the genome of Acinetobacter baumannii from a urinary tract infection case: A comprehensive analysis of resistance, virulence, and genetic mobility attributes.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- AbCro, a novel transcription factor, promotes biofilm formation and virulence in Acinetobacter baumannii.BMC microbiology · 2026Article
- Advances in phage therapy forFrontiers in microbiology · 2026Review
- Cas3 of type I-Fa CRISPR-Cas system upregulates bacterial biofilm formation and virulence in Acinetobacter baumannii.Communications biology · 2025Article
- Whole-genome sequencing ofMicrobial genomics · 2025Article
- Sub-MIC antibiotics increased the fitness cost of CRISPR-Cas inFrontiers in microbiology · 2024Article
- CRISPR-Based Gene Editing inPharmaceuticals (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
The CRISPR-Cas system is a bacterial and archaea adaptive immune system and is a newly recognized mechanism for controlling antibiotic resistance gene transfer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.